Inter-oxa-12,13(E)-didehydro-13,14-dihydro-9,10-didehydro-9-deoxy-PGD1

ABSTRACT

Prostaglandin analogs with the following cyclopentane ring structure: ##STR1## are disclosed along with intermediates useful in their preparation and processes for their preparation. These analogs are useful for some of the same pharmacological purposes as the prostaglandins, particularly and especially as blood platelet aggregation inhibitors.

The present application is a divisional application of Ser. No. 614,244, filed Sept. 17, 1975, now pending. U.S. Ser. No. 809,248, filed June 23, 1977, and also a divisional application of Ser. No. 614,244, has now issued as U.S. Pat. No. 4,099,014.

The present invention relates to prostaglandin analogs, for which the essential material constituting disclosure therefor is incorporated by reference here from U.S. Pat. No. 4,099,014. 

I claim:
 1. A prostaglandin analog of the formula ##STR2## wherein m is one to 5, inclusive; WHEREIN M₁ is ##STR3## wherein R₅ and R₆ are hydrogen or methyl, with the proviso that one of R₅ and R₆ is methyl only when the other is hydrogen;Wherein L₁ is ##STR4## or a mixture of ##STR5## wherein R₃ and R₄ are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R₃ and R₄ is fluoro only when the other is hydrogen or fluoro; Wherein R₁ is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one, two, or three chloro or aklyl of one to 3 carbon atoms, inclusive, or a pharmacologically acceptable cation; and Wherein Z₈ is

    (1) --CH.sub.2 --O--CH.sub.2 --(CH.sub.2).sub.g --CH.sub.2 --,

    (2) --(ch.sub.2).sub.2 --o--(ch.sub.2).sub.g --CH.sub.2 --, or

    (3) --(CH.sub.2).sub.3 --O--(CH.sub.2).sub.g --,

Wherein g is one, 2, or
 3. 2. A compound according to claim 1, wherein M₁ is ##STR6##
 3. A compound according to claim 1, wherein M₁ is ##STR7##
 4. A compound according to claim 3, wherein m is
 3. 5. A compound according to claim 4, wherein Z₈ is

    --CH.sub.2 --O--CH.sub.2 --(CH.sub.2).sub.g --CH.sub.2 --.


6. A compound according to claim 5, wherein g is
 3. 7. A compound according to claim 5, wherein g is one.
 8. A compound according to claim 7, wherein R₅ and R₆ are both hydrogen.
 9. A compound according to claim 8, wherein R₃ and R₄ are both hydrogen.
 10. 5-Oxa-13,14-dihydro-12,13(E)-didehydro-9-deoxy-9,10-didehydro-PGD₁, a compound according to claim
 9. 11. A compound according to claim 8, wherein R₃ and R₄ are both fluoro.
 12. 16,16-Difluoro-5-oxa-13,14-dihydro-12,13(E)-didehydro-9-deoxy-9,10-didehydro-PGD₁, a compound according to claim
 8. 13. A compound according to claim 1, wherein Z₈ is

    --(CH.sub.2).sub.3 --O--(CH.sub.2).sub.g --.


14. A compound according to claim 13, wherein g is
 3. 15. A compound according to claim 14, wherein R₅ and R₆ are both hydrogen.
 16. A compound according to claim 15, wherein R₃ and R₄ are both hydrogen.
 17. 2a,2b-Dihomo-3-oxa-13,14-dihydro-12,13(E)-didehydro-9-deoxy-9,10-didehydro-PGD.sub.1, a compound according to claim
 16. 18. A compound according to claim 15, wherein R₃ and R₄ are both fluoro.
 19. 2a,2b-Dihomo-16,16-difluoro-3-oxa-13,14-dihydro-12,13(E)-didehydro-9-deoxy-9,10-didehydro-PGD₁, a compound according to claim
 18. 20. A compound according to claim 13, wherein g is one.
 21. A compound according to claim 20, wherein R₅ and R₆ are both hydrogen.
 22. A compound according to claim 21, wherein R₃ and R₄ are both hydrogen.
 23. 3-Oxa-13,14-dihydro-12,13(E)-didehydro-9-deoxy-9,10-didehydro-PGD₁, a compound according to claim
 22. 24. A compound according to claim 21, wherein R₃ and R₄ are both fluoro.
 25. 16,16-Difluoro-3-oxa-13,14-dihydro-12,13(E)-didehydro-9-deoxy-9,10-didehydro-PGD₁, a compound according to claim
 24. 